CHR d'ORLEANS
Orléans, France
Location status: Recruiting
Location contact
Aurélie DESPUJOLS
CONTACT
May Anh NAY, PH
PRINCIPAL_INVESTIGATOR
NCT Number: NCT04472260
Acute Respiratory Distress Syndrome (ARDS) is defined according to the Berlin definition (1) as diffuse lung damage occurring in patients with a predisposing risk factor.
Positioning in the prone position (PP) has been shown to decrease mortality in patients with moderate to severe ARDS.
However, this technique is not without deleterious effects such as ventilator-associated pneumonia, endotracheal tube obstruction, development of pressure ulcers, and increased workload for the caregivers.
There are other positioning techniques such as the "upright" position, which simulates a relative verticality, which allows to increase the effects of the prone position and even in some patients to improve oxygenation without the PP in the acute phase of ARDS.
However, given the revolution caused by the use of PP in ARDS patients, verticalization have not been studied in more details.
Today, there is a bed on the market that allows patients to be truly upright without having to transfer them to a tilt table.
The investigators believe that raising ARDS patients in the acute phase is safe and feasible in routine practice. In this research protocol comparing PP and verticalization in a crossover trial design in acute ARDS patients, the investigators want to show that this technique can be safe and feasible, with the same effects on oxygenation as PP.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Orléans, France
Location status: Recruiting
Aurélie DESPUJOLS
CONTACT
May Anh NAY, PH
PRINCIPAL_INVESTIGATOR
Cross-over study, according to 4 preset sequences of 4 periods and randomly assigned. All patients will thus have the classic positioning technique (PP), as well as the technique under study (verticalization). For simplicity, the investigators will use the term "verticalization" even if the final positioning that is targeted is only a "pseudo-verticalization" to a 55° angle. The cross-over scheme with 4 sequences of 4 periods allows to get rid of the first order carry-over effect.
Progressive verticalization protocol in 7 steps from the strict supine position to a 55° inclination of the raising bed, according to the clinical responses of the patient with ARDS, as follows:
The verticalization maneuver will take place in 7 steps of 15 minutes maximum each:
S1. The first one corresponds to the flat position (strict dorsal decubitus) S2. The second is the positioning of the patient at 25° of inclination. S3. The third is the 45° positioning S4. The fourth at 55°, which corresponds to the greatest inclination imposed to the patient.
S5. The fifth corresponds to the 45° return S6. The sixth is the return to 25° S7. Finally, the investigators reposition the patient flat back.
Examinations:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.
The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours.
Time frame: Month 1
To demonstrate the feasibility and safety in routine practice of the verticalization technique for patients with moderate to severe ARDS in the acute phase.
Time frame: Hour 76
To show that verticalization of ARDS patients has the same effects on oxygenation (PaO2/FiO2 ratio) as PP.
In this crossover trial, each sequence of four treatment periods, beginning at time of randomization, will last a maximum of 75,5 hours for each patient. The last assessment will occur at a maximum of 76,5 hours from randomisation.
Time frame: Hour 76
To evaluate the impact of the positioning maneuver on quasi-static thoracopulmonary compliance.
In this crossover trial, each sequence of four treatment periods, beginning at time of randomization, will last a maximum of 75,5 hours for each patient. The last assessment will occur at a maximum of 76,5 hours from randomisation.
Time frame: Hour 76
To compare the re-ventilation of the pulmonary territories at one hour of the session (PP or verticalization) evaluated by thoracic ultrasound.
In this crossover trial, each sequence of four treatment periods, beginning at time of randomization, will last a maximum of 75,5 hours for each patient. The last assessment will occur at a maximum of 76,5 hours from randomisation.
Contact information is provided by the study sponsor or research team.
Aurélie DESPUJOLS
CONTACT
Elodie POUGOUE TOUKO
CONTACT
Centre Hospitalier Régional d'Orléans
Other
Acronym: STAND_ARDS1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06827184
Acute Respiratory Distress Syndrome, Electrical Impedance Tomography
Taipei, Taiwan
View Trial DetailsNCT05765760
Acute Respiratory Distress Syndrome, Electrical Impedance Tomography
Beijing, Beijing Municipality, China
View Trial DetailsNCT04286490
Acute Kidney Injury, Acute Respiratory Distress Syndrome
Grenoble, France
View Trial DetailsNCT06701682
ARDS, ARDS (Acute Respiratory Distress Syndrome)
Birmingham, Alabama, United States
View Trial Details